Lyme disease vaccine/treatment resistant
to Lyme D
Vaccinations in the news!!!
MEALEY'S Emerging Drugs and Devices
Pennsylvania Lawsuit Says SmithKline Hid Arthritic Lyme Vaccine Consequences
WEST CHESTER, Pa. -- A class action lawsuit filed Dec. 14 in
Pennsylvania claims the vaccine developed to prevent Lyme disease causes an incurable form of autoimmune arthritis and, for some, could produce
symptoms far worse than those brought on by the illness.
The complaint, filed in the Chester County Court of Common Pleas, alleges SmithKline Beecham, manufacturer of LYMErix, failed to warn
doctors and the general public that nearly 30 percent of the population is predisposed to a degenerative autoimmune syndrome which is triggered
by contents of the inoculation.
"Once this autoimmune reaction is triggered, it cannot be cured and can only be treated symptomatically for the remainder of the vaccine
recipient's life," the complaint says.
(Complaint. Mealey's Document #28-991217-101.)
According to the class action, SmithKline used high concentrations of a surface protein called OspA as the foundation for its vaccine. When
bitten by a Lyme-infected parasite, humans are not exposed to OspA protein. The levels of OspA that enter the blood stream at any phase of
the three-dose LYMErix vaccine, however, place patients classified by genetic type HLA-DR4+ at risk of developing a condition referred to as
"treatment-resistant" Lyme arthritis, the lawsuit says